CD33;SIGLEC3

Myeloid cell surface antigen CD33 (Sialic acid-binding Ig-like lectin 3) (Siglec-3) (gp67) (CD antigen CD33)

Homo sapiens (Human)

39825

364

Pending Verification

Myeloid cell surface antigen CD33 (Sialic acid-binding Ig-like lectin 3) (Siglec-3) (gp67) (CD antigen CD33)

N/A

MUTAGEN 100 100 N->A: Significant loss of binding to peripheral blood granulocytes. {ECO:0000269|PubMed:8702538}.; MUTAGEN 340 340 Y->A: Abolishes binding to PTPN6 and PTPN11. Increases binding of red blood cells. {ECO:0000269|PubMed:10206955}.; MUTAGEN 340 340 Y->F: Complete loss of phosphorylation by LCK. {ECO:0000269|PubMed:10887109}.; MUTAGEN 358 358 Y->A,F: Reduces binding to PTPN6. {ECO:0000269|PubMed:10556798}.; MUTAGEN 358 358 Y->F: More than 50% loss of phosphorylation by LCK. {ECO:0000269|PubMed:10887109}.

MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTTGIFPGDGSGKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTHPTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSEVRTQ

Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed:10611343, PubMed:15597323, PubMed:11320212). Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans (PubMed:7718872). Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed:28325905, PubMed:10887109). These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:10556798, PubMed:10206955, PubMed:10887109). In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed:10206955, PubMed:10887109). One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed:15597323). {ECO:0000269|PubMed:10206955, ECO:0000269|PubMed:10556798, ECO:0000269|PubMed:10611343, ECO:0000269|PubMed:10887109, ECO:0000269|PubMed:11320212, ECO:0000269|PubMed:15597323, ECO:0000269|PubMed:28325905, ECO:0000269|PubMed:7718872}.

Alternative sequence (2); Beta strand (18); Binding site (2); Chain (1); Disulfide bond (3); Domain (2); Glycosylation (5); Helix (5); Modified residue (2); Motif (2); Mutagenesis (5); Natural variant (11); Signal peptide (1); Topological domain (2); Transmembrane (1); Turn (1); Monocytic/myeloid lineage cells. In the brain, CD33 is mainly expressed on microglial cells.

Myeloid cell surface antigen CD33 (Sialic acid-binding Ig-like lectin 3) (Siglec-3) (gp67) (CD antigen CD33)

Recombinant

HEK293

Lyophilized

7.4-7.5

Sterile-filtered colorless solution

1mg/ml

Standard

PBS

SDS-PAGE

> 98%

RP-HPLC

-20°C

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.